Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Co-evolutionary dynamics of viral pathogens and human antibody response

Project description

Predicting viral-immune co-evolution

Viruses such as influenza and SARS-CoV-2 can circumvent host immune defences, and in this way evade detection. To address this, it’s important to understand how viruses and the immune system co-evolve. Unfortunately, most research focuses on either the virus or the immune response in isolation. The ERC-funded CoEvolve project aims to fill this knowledge gap. Specifically, it will study the joint evolution of viral populations and human immunity through laboratory experiments, longitudinal human studies and using viral surveillance data. The goal of CoEvolve is to create insight into the co-evolution process between viral and human populations by mapping out their interactions, with the ultimate aim of predicting how viral populations may mutate and influence vaccination strategies.

Objective

Vertebrates, like ourselves, use adaptive immune cells to protect themselves from pathogens. Predicting mutations of these pathogens, together with the immune response, is essential for the design of vaccines and therapies. CoEvolve will map the co-evolution of immune repertoires and viral populations, to forecast likely properties of future infecting strains and to design interventions that improve immune control.
Much effort has been devoted to evolving viral pathogens, but most studies focus either on viral evolution or on immune adaptation in individual hosts. Yet pathogen and host dynamics are coupled: viruses escape from immune recognition, while immune systems adapt to changing viruses. CoEvolve takes an integrative approach: we will study host immune evolution and viral evolution together and on equal footing.
We will focus on two viruses, influenza and SARS-CoV-2, that cause severe respiratory diseases. Both viruses evolve rapidly and are transmitted between hosts in acute infections. Influenza has evolved in humans over decades, while SARS-CoV-2 has entered humans more recently and is likely reaching a long-term co-evolutionary state. In both systems, we will track and predict co-evolution on multiple scales: in laboratory experiments, longitudinal human tracking studies, and globally circulating populations.
CoEvolve will develop new molecular binding and neutralisation assays for high-throughput tracking of host-pathogen immune interactions and multi-scale inference methods for coevolution. Based on these data and methods, we will
• map co-evolutionary landscapes of viral-immune molecular interactions,
• build data-driven models of human immunity and co-evolutionary dynamics,
• predict viral-immune co-evolution and inform vaccination strategies to optimize immune control.
CoEvolve addresses a fundamental science problem, to understand host-pathogen co-evolution from its molecular basis, and will break ground towards improved public health interventions.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-SyG

See all projects funded under this call

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 1 976 606,50
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 1 976 606,50

Beneficiaries (5)